-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-05-28
SWTX:NSD- (USD)
COMMON STOCK | Biotechnology |
Last Closing
USD 46.68Change
+0.22 (+0.47)%Market Cap
N/AVolume
5.36M
N/A
Verdict
Values as of: 2025-05-28
COMMON STOCK | Biotechnology |
Last Closing
USD 46.68Change
+0.22 (+0.47)%Market Cap
N/AVolume
5.36MN/A
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
VRTX | Vertex Pharmaceuticals Inc |
-5.04 (-1.13%) |
USD 128.84B |
REGN | Regeneron Pharmaceuticals Inc |
-115.11 (-19.01%) |
USD 65.38B |
ARGX | argenx NV ADR |
-7.69 (-1.32%) |
USD 34.54B |
ALNY | Alnylam Pharmaceuticals Inc |
+11.66 (+3.98%) |
USD 32.75B |
ONC | BeiGene, Ltd. |
-1.10 (-0.45%) |
USD 27.70B |
SMMT | Summit Therapeutics PLC |
-8.00 (-30.50%) |
USD 27.07B |
RPRX | Royalty Pharma Plc |
+0.24 (+0.74%) |
USD 18.40B |
INSM | Insmed Inc |
+0.52 (+0.75%) |
USD 11.84B |
INCY | Incyte Corporation |
-0.98 (-1.48%) |
USD 11.42B |
BMRN | Biomarin Pharmaceutical Inc |
-0.48 (-0.82%) |
USD 11.29B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
SAFE:CA | Global X Equal Weight Can.. | 27.62 % | 0.00 % |
-0.04 (-0.64%) |
CAD 2.65M |
HFIN:CA | Hamilton Enhanced Canadia.. | 11.55 % | 0.00 % |
-0.06 (-0.64%) |
CAD 0.19B |
HFN:CA | Hamilton Canadian Financi.. | 9.51 % | 0.00 % |
-0.11 (-0.64%) |
CAD 0.01B |
XDNA:CA | iShares Genomics Immunolo.. | 4.82 % | 0.00 % |
+0.45 (+-0.64%) |
CAD 4.62M |
HLIF:CA | Harvest Canadian Equity I.. | 3.47 % | 0.00 % |
-0.07 (-0.64%) |
CAD 0.12B |
XMV:CA | iShares MSCI Canada Minim.. | 3.09 % | 0.33 % |
-0.03 (-0.64%) |
CAD 0.29B |
CDEF:CA | Manulife Smart Defensive .. | 3.00 % | 0.00 % |
-0.02 (-0.64%) |
CAD 1.45M |
XMD:CA | iShares S&P/TSX Completio.. | 2.16 % | 0.61 % |
-0.18 (-0.64%) |
CAD 0.28B |
BBP | Virtus LifeSci Biotech Pr.. | 0.00 % | 0.79 % |
-0.42 (-0.64%) |
USD 0.02B |
CEW:CA | iShares Equal Weight Banc.. | 0.00 % | 0.60 % |
+0.01 (+-0.64%) |
CAD 0.23B |
DXM:CA | 0.00 % | 0.67 % |
N/A |
N/A | |
FIE:CA | iShares Canadian Financia.. | 0.00 % | 0.97 % |
+0.02 (+-0.64%) |
CAD 1.06B |
FLI:CA | CI U.S. & Canada Lifeco C.. | 0.00 % | 0.92 % |
+0.07 (+-0.64%) |
CAD 0.09B |
HAL:CA | Global X Active Canadian .. | 0.00 % | 0.78 % |
-0.04 (-0.64%) |
CAD 0.12B |
HEF:CA | 0.00 % | 0.83 % |
N/A |
N/A | |
HPR:CA | Global X Active Preferred.. | 0.00 % | 0.63 % |
-0.03 (-0.64%) |
CAD 0.95B |
PR:CA | Lysander-Slater Preferred.. | 0.00 % | 1.03 % |
-0.01 (-0.64%) |
CAD 0.08B |
IDNA | iShares Genomics Immunolo.. | 0.00 % | 0.00 % |
-0.20 (-0.64%) |
USD 0.10B |
RODM | Hartford Multifactor Deve.. | 0.00 % | 0.31 % |
+0.07 (+-0.64%) |
N/A |
BANK:CA | Evolve Canadian Banks and.. | 0.00 % | 0.39 % |
-0.09 (-0.64%) |
CAD 0.40B |
BNC:CA | Purpose Canadian Financia.. | 0.00 % | 0.68 % |
-0.20 (-0.64%) |
N/A |
CDIV:CA | Manulife Smart Dividend E.. | 0.00 % | 0.00 % |
-0.06 (-0.64%) |
CAD 0.64B |
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 29.20% | 87% | B+ | 89% | A- | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 29.20% | 87% | B+ | 89% | A- | ||
Trailing 12 Months | |||||||
Capital Gain | 14.24% | 79% | B- | 72% | C | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 14.24% | 79% | B- | 71% | C- | ||
Trailing 5 Years | |||||||
Capital Gain | 22.62% | 82% | B | 57% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 22.62% | 82% | B | 50% | F | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 3.39% | 57% | F | 54% | F | ||
Dividend Return | 3.39% | 57% | F | 50% | F | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 49.65% | 63% | D | 36% | F | ||
Risk Adjusted Return | 6.83% | 60% | D- | 44% | F | ||
Market Capitalization | N/A | N/A | N/A | N/A | N/A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This stock has shown below median earnings growth in the previous 5 years compared to its sector